NRG
CKPT

Nemes Rush Group’s Checkpoint Therapeutics CKPT Stock Holding History

Nemes Rush Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,075
Closed -$5.13K – 667
2023
Q2 		$5.13K Buy
+2,075
New +$5.67K ﹤0.01% 486

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 35.19% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Nemes Rush Group's CKPT Position: Q3 2023 in Review

Nemes Rush Group sold out of Checkpoint Therapeutics (CKPT) in Q3 2023, closing a stake of 2,075 shares — an estimated $5.13K sold.

Nemes Rush Group first reported a position in CKPT in Q2 2023 and held it in 1 quarter. The position peaked at $5.13K in Q2 2023. 39 funds tracked by Wall St. Rank hold CKPT as of Q3 2023.

  • Nemes Rush Group reported no remaining Checkpoint Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Nemes Rush Group sold 2,075 Checkpoint Therapeutics shares in Q3 2023, an estimated $5.13K.
  • Nemes Rush Group first reported a position in Checkpoint Therapeutics in Q2 2023 and held it in 1 quarter.
  • Nemes Rush Group's Checkpoint Therapeutics position peaked at $5.13K in Q2 2023.
  • 39 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2023.

Based on Nemes Rush Group's 13F filing for Q3 2023, filed 9 Nov 2023.